Benitec Biopharma Inc. (BNTC): Cash & Equivalents
$179.97M
As of 2026-06-30
n/m
3-year compound annual growth
+55.5%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $179.97M | +84.1% | 2026-09-14, Balance as of period end |
| 2025-06-30 | $97.74M | +92.2% | 2026-09-14, Balance as of period end |
| 2024-06-30 | $50.87M | n/m | 2026-03-20, Balance as of period end |
| 2023-06-30 | $2.48M | -39.0% | 2024-09-26, Balance as of period end |
| 2022-06-30 | $4.06M | -79.5% | 2023-09-21, Balance as of period end |
| 2021-06-30 | $19.77M | +101.7% | 2022-09-02, Balance as of period end |
| 2020-06-30 | $9.80M | -37.6% | 2021-09-20, Balance as of period end |
| 2019-06-30 | $15.72M | n/a | 2020-09-23, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | $179.97M | +84.1% |
| Alto Neuroscience, Inc. (ANRO) | 2025-12-31 | $176.48M | +4.9% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $34.33M | -48.5% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $79.38M | +38.6% |
| PepGen Inc. (PEPG) | 2025-12-31 | $60.51M | +22.4% |
| Adicet Bio, Inc. (ACET) | 2025-12-31 | $38.92M | -31.1% |
| Trevi Therapeutics, Inc. (TRVI) | 2025-12-31 | $18.91M | -44.5% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $37.73M | -18.1% |
| Eledon Pharmaceuticals, Inc. (ELDN) | 2025-12-31 | $22.81M | +11.0% |
Compare BNTC, ANRO, LXRX, FBIO side by side · Screen every company in Pharmaceutical Preparations ↗